Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Pleiotropic Drugs against Alzheimer’s Disease

Version 1 : Received: 29 July 2023 / Approved: 31 July 2023 / Online: 31 July 2023 (10:41:17 CEST)

A peer-reviewed article of this Preprint also exists.

Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics 2023, 15, 2382. Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics 2023, 15, 2382.

Abstract

The multifactorial nature of some diseases, and in particular neurodegenerative diseases such as Alzheimer’s disease, frequently requires the use of several drugs. These drug cocktails are not without drawbacks in terms of increased adverse effects, drug-drug interactions or adherence to treatment. The concept of pleiotropic drugs, which combine, within a single molecule, several activities directed against distinct therapeutic targets, makes it possible to overcome some of these problems. In addition, these pleiotropic drugs, generally, lead to the expression of a synergy of effects, sometimes greater than that observed with a combination of drugs. This article will review, through recent examples, the different kinds of pleiotropic drugs being studied or already present on the market of medicines.

Keywords

Drug; Pleiotropic; Neurodegeneration; Alzheimer

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.